Abstract
Background The aim of this study was to explore potentially novel plasma protein biomarkers for lung adenocarcinoma (LUAD).
Methods A plasma proteomics analysis was carried out in LUAD cases and healthy controls. Candidate protein biomarkers were validated in 102 LUAD cases and 102 matched healthy controls. The same LUAD tumor tissues were detected to explore the correlation between the expression of candidate proteins in tissues and plasma and vascular normalization. A LUAD active metastasis mice model was constructed to explore the role of candidate proteins for lung metastasis.
Results In the screening phase, 5 candidate proteins were selected. In the validation phase, GPI and PGD were verified to be upregulated in plasma from LUAD patients. The expression of GPI in tumor tissue was positively correlated with the expression of GPI in plasma and negatively correlated with the normalization of tumor blood vessels. Meanwhile, a negative correlation between the expression of GPI and PGD in plasma and tumor vascular normalization was discovered. In the LUAD active metastasis model, the lowest levels of vascular normalization and the highest expression of GPI and PGD were found in mice with lung metastases
Conclusion This study found that GPI and PGD may be potential diagnostic plasma biomarkers for LUAD, providing new clues to assist in LUAD early screening. Meanwhile, monitoring the concentration of GPI and PGD in plasma may reflect the level of vascular normalization within the tumor and infer the risk of metastasis and malignancy of the tumor.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (82273715, 82203771), the National Key Research and Development Program of China (2022YFC2503202), the Science and Technology Program of Nantong City (MS22022062, JC22022002), the Talent Training Climbing Action Plan Project of the Sixth People's Hospital of Nantong, and the Postgraduate Research and Practice Innovation Program of Jiangsu Province (KYCX21-3126, KYCX20-2852).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics committee of Nantong University gave ethical approval for this work (Approval No. 2022-2).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors